Abstract 19P
Background
SCLC is highly heterogeneous and can be divided into NE (Neuroendocrine)-high and NE-low groups according to 50 genes on transcriptomic level, harboring different immune microenvironments and potential immunotherapy reactivity. However, this is still far from clinical application since the current three classic NE markers (ChrA, Syn,and CD56) are not very satisfactory either for specificity or sensitivity. It is necessary to explore novel NE markers, that are both close to NE gene subtyping and feasible for clinicopathological use.
Methods
Quantitative detection of NE mRNA genes by Nanostring nCounter as well as INSM1 protein by immunohistochemistry was performed simultaneously on 48 whole slides as testing group. Spearman correlation was applied for consistency analysis of 50 genes and INSM1 protein expression, and the best cut-off for INSM1 expression was validated on 247 tissue microarrays for comparison of the 3 traditional NE protein markers for specificity and sensibility as well as prognostic significance.
Results
In 48 cases, quantitative detection revealed 83.3% for NE-high and 16.7% for NE-low, while for INSM1 protein grouping, it was 79.2% (H-score>100) for NE(INSM1)-high and 20.8% (H-score<=100) for NE(INSM1)-low. NE subtypes defined by INSM1 protein and NE genes had significant consistency in terms of proportion (p=0.026). In addition, NE groups also had consistent clinical characteristics and prognostic trend in the two levels. Patients with NE-high and NE(INSM1)-high tended to be in the advanced stage. Patients with NE-high and NE(INSM1)-high subtypes have a tendency to poor prognosis. In 247 cases of validation exploration, INSM1 expression was positively correlated with 3 classical markers, moreover, in triple-negative cases, INSM1 showed a favorable positive rate (1.5%, 3/198). In addition, NE(INSM1)-high patients showed more bronchial invasion and tumor thrombosis than that of NE(INSM1)-low ones (p<0.05), and the OS rates in the NE(INSM1)-high group were slightly lower than those in the NE(INSM1)-low group.
Conclusions
INSM1 has great potential as a marker of NE differentiation and subgrouping, and also shows a certain correlation with prognosis and some clinicopathological factors.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract